Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Alnylam Pharmaceuticals
(NQ:
ALNY
)
245.84
+5.69 (+2.37%)
Streaming Delayed Price
Updated: 12:13 PM EDT, Jun 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Alnylam Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
3 Top Biotech Stocks Defying the Bear Market
October 11, 2022
Bear market, shmear market. These biotech stocks are soaring despite the market downturn.
Via
The Motley Fool
Alnylam's Lumasiran Scores Expanded FDA Approval For Ultra Rare Genetic Disease
October 07, 2022
Via
Benzinga
Where Alnylam Pharmaceuticals Stands With Analysts
October 03, 2022
Over the past 3 months, 12 analysts have published their opinion on Alnylam Pharmaceuticals (NASDAQ:ALNY) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
What 12 Analyst Ratings Have To Say About Alnylam Pharmaceuticals
October 03, 2022
Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Analyst Ratings for Alnylam Pharmaceuticals
October 03, 2022
Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Alnylam Reinforces Patisiran Data In Stiff Heart Disorder Before Heading For FDA Approval
October 03, 2022
Via
Benzinga
Analyst Ratings for Alnylam Pharmaceuticals
September 09, 2022
Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) within the last quarter:
Via
Benzinga
Where Alnylam Pharmaceuticals Stands With Analysts
August 04, 2022
Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings:
Via
Benzinga
AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know
October 02, 2022
Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the...
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
September 22, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Analysts Put Alnylam On Upside Catalyst Watch Ahead Of Upcoming Data From Lead Program
September 20, 2022
Via
Benzinga
Intellia Therapeutics Looks To Repeat Its Landmark Success In CRISPR Gene Editing
September 16, 2022
Intellia tested its CRISPR approach in cardiomyopathy and hereditary angioedema.
Via
Investor's Business Daily
Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary
September 15, 2022
Via
Benzinga
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin
September 15, 2022
The market is struggling, yet biotech stocks are acting like it's good times again. Here's why.
Via
Investor's Business Daily
Alnylam/Regeneron-Backed NASH Candidate Shows Encouraging Safety Profile In Healthy Volunteers
September 15, 2022
Via
Benzinga
Why Alnylam Pharmaceuticals Shares Are Falling
September 12, 2022
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) shares are trading lower by 4.97% to $212.18 Monday morning after the company announced a proposed offering of $900 million convertible
Via
Benzinga
Where Alnylam Pharmaceuticals Stands With Analysts
September 09, 2022
Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings:
Via
Benzinga
Important Biotech Catalysts For September 8, 2022 - End Of The Day Summary
September 08, 2022
Via
Benzinga
Alnylam Shares Detailed Patisiran Data From Rare Disease Study
September 08, 2022
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) announced positive results from the APOLLO-B Phase 3 study of patisiran for transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.
Via
Benzinga
Alnylam Posts Mid-Stage Study Data From Regeneron-Partnered Kidney Disease Drug
August 29, 2022
Via
Benzinga
10 Biotech Stocks Are Up 40% Or More This Year, Including Karuna, Axsome And Others
August 29, 2022
These names are benefitting from M&A, clinical data and promising regulatory actions.
Via
Investor's Business Daily
Moderna Entangles Pfizer/BioNTech In COVID-19 Vaccine Patent Lawsuits: All You Need To Know
August 26, 2022
Moderna Inc (NASDAQ: MRNA) has
Via
Benzinga
Will Investors Notice Exciting Sign On Alnylam Pharmaceuticals Chart?
August 17, 2022
If history is any guide, there may be good fortune ahead for shares of Alnylam Pharmaceuticals (NASDAQ:ALNY). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be...
Via
Benzinga
If You Invested $100 In This Stock 15 Years Ago, You Would Have $1,000 Today
August 12, 2022
Alnylam Pharmaceuticals (NASDAQ:ALNY) has outperformed the market over the past 15 years by 9.06% on an annualized basis producing an average annual return of 16.5%. Currently, Alnylam...
Via
Benzinga
Pfizer Is Reportedly In 'Advanced Talks' To Buy Global Blood Therapeutics For $5 Billion
August 05, 2022
Shares of Pfizer's rumored takeover target have rocketed for two days running.
Via
Investor's Business Daily
Alnylam's Hot Streak Cools As Expert Questions Uptake For Its Heart Drug
August 05, 2022
The company will compete with Pfizer, which already has an approved drug.
Via
Investor's Business Daily
Stock Market Rally Mixed As Oil Prices Fall, Job Growth Hot: Weekly Review
August 05, 2022
The Nasdaq and small caps rose while the S&P 500 is hitting resistance.
Via
Investor's Business Daily
Intellia Gives Back Alnylam-Inspired Gains As Gene-Editing Safety Questioned
August 04, 2022
Intellia is backing off the higher dose of a gene-editing drug in cardiomyopathy patients.
Via
Investor's Business Daily
Alnylam Pharmaceuticals Earnings Perspective: Return On Capital Employed
August 04, 2022
Alnylam Pharmaceuticals (NASDAQ:ALNY) brought in sales totaling $224.82 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 15.42%, resulting in a loss of $277.40...
Via
Benzinga
This Biotechnology Stock Jumped Over 360%; Here Are 106 Biggest Movers From Yesterday
August 04, 2022
Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) shares surged 360.5% to settle at $19.80 on Wednesday on above-average volume.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.